SPR Therapeutics Closes $37 Million Growth Equity Financing for Commercial Expansion of its SPRINT® PNS System
18 oct. 2021 09h17 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Oct. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has...
Researchers Unveil a New Theory Explaining Long-term Pain Relief
15 mars 2021 09h30 HE
|
SPR Therapeutics, Inc.
CLEVELAND, March 15, 2021 (GLOBE NEWSWIRE) -- A novel theory recently published in the Journal of Pain Research proposes mechanisms by which a 60-day treatment using percutaneous peripheral nerve...
SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA
02 mars 2021 10h45 HE
|
SPR Therapeutics, Inc.
CLEVELAND, March 02, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of...
Study of Sprint Peripheral Nerve Stimulation System Demonstrates 12 Months of Low Back Pain Relief Following 60-Day Treatment
21 janv. 2020 08h55 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Jan. 21, 2020 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced publication of a prospective case series regarding...
SPR Therapeutics Announces 1000th Sprint PNS Procedure
04 déc. 2019 08h30 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced today the successful commercial placement of its 1000th...
SPR Therapeutics’ SPRINT Peripheral Nerve Stimulation System Significantly Reduces Opioid Use in Patients with Low Back Pain, Interim Data Show
21 août 2019 08h30 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio and KISSIMMEE, Florida, Aug. 21, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, presented interim results today on the...
SPR Therapeutics Announces First Use of SPRINT endura Peripheral Nerve Stimulation System to treat Complex Regional Pain Syndrome
15 nov. 2018 08h00 HE
|
SPR Therapeutics, Inc.
SPRINT System is the least invasive PNS device for CRPS CLEVELAND, Nov. 15, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today...
SPR Therapeutics Awarded $10M From U.S. Department of Defense
02 oct. 2018 10h30 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Oct. 02, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, has been awarded two new grants and one new contract from the U.S....
SPR Therapeutics Announces First Use of SPRINT extensa Dual-lead Peripheral Nerve Stimulation System to Treat Low Back Pain
25 sept. 2018 10h10 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced that Christopher Gilmore, MD of Carolinas Pain...
FDA Clears SPR Therapeutics’ Non-opioid SPRINT endura and extensa Peripheral Nerve Stimulation Systems for Pain Management
16 août 2018 08h30 HE
|
SPR Therapeutics, Inc.
SPRINT® is the First and Only Dual Lead Capable PNS Platform Company also provides first look at 12-month durability outcomes following 60-day SPRINT therapy CLEVELAND, Aug. 16, 2018 (GLOBE...